NasdaqGS:PRAXBiotechs
Why Praxis Precision Medicines (PRAX) Is Up 6.6% After Dual NDA Timeline and Investor Push - And What's Next
Praxis Precision Medicines recently presented at Guggenheim Securities’ Emerging Outlook: Biotech Summit 2026 and scheduled its fourth-quarter and full-year 2025 results and corporate update for February 19, 2026, highlighting upcoming regulatory milestones for ulixacaltamide and relutrigine, both with FDA Breakthrough Therapy Designation and planned New Drug Application submissions by mid-February.
What stands out is how tightly the company’s investor outreach, conference appearances and...